FOXO TECHNOLOGIES INC.

Vector BioSource

We believe our most recent acquisition of Vector establishes FOXO as a growing player in the pharmaceutical services sector. Vector sources biospecimens (blood, urine) and sells such biospecimens to the biotechnology and pharmaceutical research sectors both in the US and abroad. Since the acquisition in late 2025, we have focused on expanding the number of strategic customers and suppliers for Vector.

We are also evaluating a significant acquisition in the space. While there can be no assurance that this transaction will be completed, if successful, we expect this acquisition to close in the second half of the year and, based on current estimates, to add in excess of $10 million of annual revenues to Vector.

To summarize, the existing business of the Company continues to deliver improved revenues and efficiencies. The Company has had limited access to new capital in 2026 to accelerate growth. It is hoped that achievements in the first half of the year and plans to up-list to a recognized stock exchange can remove this limitation and facilitate adequate capital to accelerate organic growth and acquisitions to where the Company becomes self-sustainable and delivers value for our shareholders.

Sincerely,

Seamus Lagan

Chief Executive Officer